CORMEDIX INC (CRMD) Fundamental Analysis & Valuation

NASDAQ:CRMD • US21900C3088

Current stock price

7.05 USD
+0.03 (+0.43%)
At close:
7.07 USD
+0.02 (+0.28%)
After Hours:

This CRMD fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

6

1. CRMD Profitability Analysis

1.1 Basic Checks

  • In the past year CRMD was profitable.
  • CRMD had a positive operating cash flow in the past year.
  • CRMD had negative earnings in 4 of the past 5 years.
  • In the past 5 years CRMD reported 4 times negative operating cash flow.
CRMD Yearly Net Income VS EBIT VS OCF VS FCFCRMD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50M -50M 100M 150M

1.2 Ratios

  • With an excellent Return On Assets value of 19.74%, CRMD belongs to the best of the industry, outperforming 97.40% of the companies in the same industry.
  • CRMD has a Return On Equity of 40.23%. This is amongst the best in the industry. CRMD outperforms 97.40% of its industry peers.
  • CRMD's Return On Invested Capital of 18.20% is amongst the best of the industry. CRMD outperforms 94.79% of its industry peers.
Industry RankSector Rank
ROA 19.74%
ROE 40.23%
ROIC 18.2%
ROA(3y)-17.27%
ROA(5y)-28.12%
ROE(3y)-15.67%
ROE(5y)-29.18%
ROIC(3y)N/A
ROIC(5y)N/A
CRMD Yearly ROA, ROE, ROICCRMD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -100 -200 -300 -400 -500

1.3 Margins

  • The Profit Margin of CRMD (52.31%) is better than 97.40% of its industry peers.
  • Looking at the Operating Margin, with a value of 48.17%, CRMD belongs to the top of the industry, outperforming 99.48% of the companies in the same industry.
  • With an excellent Gross Margin value of 88.46%, CRMD belongs to the best of the industry, outperforming 91.15% of the companies in the same industry.
  • In the last couple of years the Gross Margin of CRMD has grown nicely.
Industry RankSector Rank
OM 48.17%
PM (TTM) 52.31%
GM 88.46%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.06%
GM growth 5Y47.9%
CRMD Yearly Profit, Operating, Gross MarginsCRMD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -10K -20K -30K -40K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. CRMD Health Analysis

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), CRMD is creating value.
  • The number of shares outstanding for CRMD has been increased compared to 1 year ago.
  • CRMD has more shares outstanding than it did 5 years ago.
  • CRMD has a worse debt/assets ratio than last year.
CRMD Yearly Shares OutstandingCRMD Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M
CRMD Yearly Total Debt VS Total AssetsCRMD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M

2.2 Solvency

  • Based on the Altman-Z score of 1.75, we must say that CRMD is in the distress zone and has some risk of bankruptcy.
  • CRMD's Altman-Z score of 1.75 is fine compared to the rest of the industry. CRMD outperforms 60.94% of its industry peers.
  • CRMD has a debt to FCF ratio of 0.84. This is a very positive value and a sign of high solvency as it would only need 0.84 years to pay back of all of its debts.
  • CRMD has a Debt to FCF ratio of 0.84. This is amongst the best in the industry. CRMD outperforms 95.83% of its industry peers.
  • A Debt/Equity ratio of 0.36 indicates that CRMD is not too dependend on debt financing.
  • The Debt to Equity ratio of CRMD (0.36) is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.36
Debt/FCF 0.84
Altman-Z 1.75
ROIC/WACC2.07
WACC8.77%
CRMD Yearly LT Debt VS Equity VS FCFCRMD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 100M 200M 300M 400M

2.3 Liquidity

  • CRMD has a Current Ratio of 2.11. This indicates that CRMD is financially healthy and has no problem in meeting its short term obligations.
  • CRMD's Current ratio of 2.11 is in line compared to the rest of the industry. CRMD outperforms 40.63% of its industry peers.
  • A Quick Ratio of 1.94 indicates that CRMD should not have too much problems paying its short term obligations.
  • Looking at the Quick ratio, with a value of 1.94, CRMD is in line with its industry, outperforming 44.79% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.11
Quick Ratio 1.94
CRMD Yearly Current Assets VS Current LiabilitesCRMD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

7

3. CRMD Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 712.12% over the past year.
  • The Revenue has grown by 617.03% in the past year. This is a very strong growth!
  • Measured over the past years, CRMD shows a very strong growth in Revenue. The Revenue has been growing by 319.48% on average per year.
EPS 1Y (TTM)712.12%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-18.18%
Revenue 1Y (TTM)617.03%
Revenue growth 3Y1545.19%
Revenue growth 5Y319.48%
Sales Q2Q%312.11%

3.2 Future

  • CRMD is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 14.22% yearly.
  • The Revenue is expected to grow by 12.26% on average over the next years. This is quite good.
EPS Next Y-32.63%
EPS Next 2Y-26.93%
EPS Next 3Y14.85%
EPS Next 5Y14.22%
Revenue Next Year-1.16%
Revenue Next 2Y-3.28%
Revenue Next 3Y3.93%
Revenue Next 5Y12.26%

3.3 Evolution

  • Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
CRMD Yearly Revenue VS EstimatesCRMD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 200M 400M 600M 800M
CRMD Yearly EPS VS EstimatesCRMD Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 2 -2 4

More info and screens

Find the best growth stocksShow best growing peers

8

4. CRMD Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings ratio is 3.49, which indicates a rather cheap valuation of CRMD.
  • Based on the Price/Earnings ratio, CRMD is valued cheaply inside the industry as 97.40% of the companies are valued more expensively.
  • CRMD is valuated cheaply when we compare the Price/Earnings ratio to 25.60, which is the current average of the S&P500 Index.
  • The Price/Forward Earnings ratio is 5.18, which indicates a rather cheap valuation of CRMD.
  • Based on the Price/Forward Earnings ratio, CRMD is valued cheaper than 94.79% of the companies in the same industry.
  • When comparing the Price/Forward Earnings ratio of CRMD to the average of the S&P500 Index (22.84), we can say CRMD is valued rather cheaply.
Industry RankSector Rank
PE 3.49
Fwd PE 5.18
CRMD Price Earnings VS Forward Price EarningsCRMD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40 50

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, CRMD is valued cheaper than 97.92% of the companies in the same industry.
  • Based on the Price/Free Cash Flow ratio, CRMD is valued cheaply inside the industry as 97.92% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 3.23
EV/EBITDA 3.34
CRMD Per share dataCRMD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2 3 4 5

4.3 Compensation for Growth

  • CRMD has a very decent profitability rating, which may justify a higher PE ratio.
  • CRMD's earnings are expected to grow with 14.85% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-26.93%
EPS Next 3Y14.85%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. CRMD Dividend Analysis

5.1 Amount

  • No dividends for CRMD!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

CRMD Fundamentals: All Metrics, Ratios and Statistics

CORMEDIX INC

NASDAQ:CRMD (4/2/2026, 8:16:52 PM)

After market: 7.07 +0.02 (+0.28%)

7.05

+0.03 (+0.43%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)03-05
Earnings (Next)05-04
Inst Owners54.97%
Inst Owner Change0.68%
Ins Owners8%
Ins Owner Change11.55%
Market Cap557.30M
Revenue(TTM)311.71M
Net Income(TTM)163.06M
Analysts83.08
Price Target14.86 (110.78%)
Short Float %21.79%
Short Ratio8.64
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)6.55%
Min EPS beat(2)-78.38%
Max EPS beat(2)91.47%
EPS beat(4)3
Avg EPS beat(4)21.25%
Min EPS beat(4)-78.38%
Max EPS beat(4)91.47%
EPS beat(8)7
Avg EPS beat(8)25.63%
EPS beat(12)8
Avg EPS beat(12)14.94%
EPS beat(16)11
Avg EPS beat(16)14.44%
Revenue beat(2)1
Avg Revenue beat(2)9.06%
Min Revenue beat(2)-0.73%
Max Revenue beat(2)18.84%
Revenue beat(4)3
Avg Revenue beat(4)9.07%
Min Revenue beat(4)-0.73%
Max Revenue beat(4)18.84%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-9.73%
PT rev (3m)-23.31%
EPS NQ rev (1m)-29.29%
EPS NQ rev (3m)-34.84%
EPS NY rev (1m)-16.36%
EPS NY rev (3m)-46%
Revenue NQ rev (1m)-4.1%
Revenue NQ rev (3m)-18.05%
Revenue NY rev (1m)-0.79%
Revenue NY rev (3m)-29.9%
Valuation
Industry RankSector Rank
PE 3.49
Fwd PE 5.18
P/S 1.79
P/FCF 3.23
P/OCF 3.18
P/B 1.38
P/tB N/A
EV/EBITDA 3.34
EPS(TTM)2.02
EY28.65%
EPS(NY)1.36
Fwd EY19.3%
FCF(TTM)2.19
FCFY31%
OCF(TTM)2.21
OCFY31.41%
SpS3.94
BVpS5.13
TBVpS-0.05
PEG (NY)N/A
PEG (5Y)N/A
Graham Number15.27
Profitability
Industry RankSector Rank
ROA 19.74%
ROE 40.23%
ROCE 23.03%
ROIC 18.2%
ROICexc 23.56%
ROICexgc 125.82%
OM 48.17%
PM (TTM) 52.31%
GM 88.46%
FCFM 55.43%
ROA(3y)-17.27%
ROA(5y)-28.12%
ROE(3y)-15.67%
ROE(5y)-29.18%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.06%
GM growth 5Y47.9%
F-Score5
Asset Turnover0.38
Health
Industry RankSector Rank
Debt/Equity 0.36
Debt/FCF 0.84
Debt/EBITDA 0.88
Cap/Depr 15.53%
Cap/Sales 0.73%
Interest Coverage 8831.82
Cash Conversion 106.29%
Profit Quality 105.97%
Current Ratio 2.11
Quick Ratio 1.94
Altman-Z 1.75
F-Score5
WACC8.77%
ROIC/WACC2.07
Cap/Depr(3y)171.72%
Cap/Depr(5y)634.7%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)712.12%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-18.18%
EPS Next Y-32.63%
EPS Next 2Y-26.93%
EPS Next 3Y14.85%
EPS Next 5Y14.22%
Revenue 1Y (TTM)617.03%
Revenue growth 3Y1545.19%
Revenue growth 5Y319.48%
Sales Q2Q%312.11%
Revenue Next Year-1.16%
Revenue Next 2Y-3.28%
Revenue Next 3Y3.93%
Revenue Next 5Y12.26%
EBIT growth 1Y771.58%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-25.09%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y440.6%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y445.84%
OCF growth 3YN/A
OCF growth 5YN/A

CORMEDIX INC / CRMD Fundamental Analysis FAQ

What is the fundamental rating for CRMD stock?

ChartMill assigns a fundamental rating of 6 / 10 to CRMD.


Can you provide the valuation status for CORMEDIX INC?

ChartMill assigns a valuation rating of 8 / 10 to CORMEDIX INC (CRMD). This can be considered as Undervalued.


What is the profitability of CRMD stock?

CORMEDIX INC (CRMD) has a profitability rating of 6 / 10.


What is the expected EPS growth for CORMEDIX INC (CRMD) stock?

The Earnings per Share (EPS) of CORMEDIX INC (CRMD) is expected to decline by -32.63% in the next year.